ECL:NYSEEcolab Inc. Analysis
Data as of 2026-05-23 - not real-time
$253.32
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Ecolab delivered a robust earnings beat with double‑digit EPS growth and solid top‑line expansion, reinforcing its resilient business model across water, hygiene and life‑science segments. The stock is currently trading below its short‑ and medium‑term moving averages and under the long‑term trend line, indicating a bearish technical backdrop, while momentum indicators sit in a neutral zone and the MACD histogram has just turned positive, hinting at a potential short‑term bounce.
Valuation remains stretched, with market pricing far above intrinsic estimates, yet the company generates strong operating cash flow that comfortably funds its modest dividend. Analyst consensus stays bullish with price targets well above the current level, but the market’s “Extreme Greed” sentiment may be inflating expectations. Investors should weigh the upside from earnings momentum against the downside risk from high valuation and a prevailing bearish trend.
Valuation remains stretched, with market pricing far above intrinsic estimates, yet the company generates strong operating cash flow that comfortably funds its modest dividend. Analyst consensus stays bullish with price targets well above the current level, but the market’s “Extreme Greed” sentiment may be inflating expectations. Investors should weigh the upside from earnings momentum against the downside risk from high valuation and a prevailing bearish trend.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Earnings beat and positive cash flow
- Price near technical support level
- MACD histogram turning positive
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Revenue and margin expansion
- Analyst consensus and price‑target upside
- Sustainable dividend with low payout ratio
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Secular demand for water and hygiene solutions
- Strong free cash flow generation
- Valuation gap relative to intrinsic fair value
Key Metrics & Analysis
Financial Health
Revenue Growth10.00%
Profit Margin12.80%
P/E Ratio34.2
ROE22.43%
ROA8.01%
Debt/Equity92.37
P/B Ratio7.1
Op. Cash Flow$3.0B
Free Cash Flow$1.6B
Technical Analysis
TrendBearish
RSI44.8
Support$243.15
Resistance$269.96
MA 20$254.75
MA 50$262.83
MA 200$271.89
MACDBullish
VolumeIncreasing
Fear & Greed Index91.61
Valuation
Fair Value$80.78
Target Price$315.95
Upside/Downside24.72%
GradeOvervalued
TypeGrowth
Dividend Yield1.15%
Risk Assessment
Beta0.68
Volatility21.33%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.